News

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...
Cigna’s (NYSE:CI) health services arm ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much ...
Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...
Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 drugs ... respectively—to cap patients' monthly costs at $200.
Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...
Evernorth — the Cigna division ... cost per prescription of GLP-1 medications," Evernorth said. Evernorth said patients will be able to get the drugs with the $200 copay through a "broad network ...
The health services arm of The Cigna Group CI, Evernorth ... For patients, the monthly copay for GLP-1 weight loss medications will be capped at $200 or less, offering a more affordable option ...
Cigna is doubling ... also link patients to copay assistance programs for which they may be eligible. Evanko noted that one in ten Americans is set to be on a GLP-1 drug, but significant barriers ...
The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)'s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly's Zepbound was ...